Aventis Diabetes Outlook: Lantus Has Brighter Future Than Exubera, Firm Says

Aventis expects the long-acting insulin Lantus will be a bigger product than Exubera (inhaled insulin) in the diabetes market, Management Board Chairman Igor Landau maintained